Johnson & Johnson (NYSE:JNJ) Shares Bought by Seizert Capital Partners LLC

Key Points

• Seizert Capital Partners LLC increased its position in Johnson & Johnson by 1.4%, owning 245,155 shares valued at approximately $40.6 million, making it the firm's 24th largest investment.
• Johnson & Johnson reported $2.77 earnings per share for the last quarter, exceeding expectations, while its revenue hit $23.74 billion, a 5.8% increase year-over-year.
• The company recently declared a quarterly dividend of $1.30 per share, yielding 3.09%, with a payout ratio of 55.61%.

Seizert Capital Partners LLC raised its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 1.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 245,155 shares of the company's stock after purchasing an additional 3,385 shares during the period. Johnson & Johnson accounts for 1.9% of Seizert Capital Partners LLC's investment portfolio, making the stock its 24th biggest position. Seizert Capital Partners LLC's holdings in Johnson & Johnson were worth $40,657,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Geode Capital Management LLC raised its position in Johnson & Johnson by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company's stock worth $8,321,881,000 after purchasing an additional 1,561,036 shares during the period. Northern Trust Corp boosted its stake in Johnson & Johnson by 12.3% during the fourth quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock worth $4,456,201,000 after acquiring an additional 3,363,235 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Johnson & Johnson by 26.4% during the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after acquiring an additional 4,842,582 shares in the last quarter. Invesco Ltd. lifted its stake in shares of Johnson & Johnson by 6.5% in the fourth quarter. Invesco Ltd. now owns 19,126,079 shares of the company's stock worth $2,766,014,000 after buying an additional 1,171,975 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in shares of Johnson & Johnson by 2.5% in the first quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company's stock worth $3,031,955,000 after buying an additional 448,666 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Down 1.5%

Shares of JNJ traded down $2.50 during mid-day trading on Thursday, hitting $164.76. 9,876,897 shares of the company's stock were exchanged, compared to its average volume of 8,007,298. The company has a market cap of $396.81 billion, a price-to-earnings ratio of 17.62, a P/E/G ratio of 2.13 and a beta of 0.41. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The stock's 50-day moving average is $157.18 and its 200-day moving average is $156.44.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same quarter last year, the company earned $2.82 earnings per share. The firm's revenue was up 5.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's payout ratio is currently 55.61%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on JNJ shares. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price objective for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Erste Group Bank upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Wall Street Zen lowered shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 18th. Finally, Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Nine research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.